Glenmark Pharma has reported a rise of 23.5% (YoY) in its first quarter FY12 net profit. During the period, consolidated net profit increased to Rs 210 crore against Rs 170 crore in the corresponding quarter last fiscal year.
Consolidated net sales jumped over 27% to Rs 868 crore from Rs 682 crore year-on-year. Out-licensing revenue in the same period stood at Rs 111 crore.
Company reported decline in EBITDA margin in the April-June quarter to 31.4% versus 32% Q1FY11.
Source: www.moneycontrol.com
Thanks,
Gaurav Agarwal
Head Dealer
DENIP Consultants Pvt Ltd
No comments:
Post a Comment